Pharma BD Deal Intelligence

Merck & Co., Inc. / Afferent Pharmaceuticals, Inc.

2016 · Acquisition/Merger · $1.2B · Complete

Merck acquired clinical-stage Afferent Pharmaceuticals for $500M cash upfront plus up to $750M tied to clinical and commercial milestones (~$1.25B total). Lead asset AF-219, a selective P2X3 antagonist in Phase 2b for refractory chronic cough and Phase 2 in IPF cough. Closed Q3 2016. Later renamed gefapixant (MK-7264).

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Jun 08, 2016
• Closed Jun 30, 2016
• Deal value $1.2B
• Deal type Acquisition/Merger
• Therapeutic area Refractory chronic cough; idiopathic pulmonary fibrosis (IPF) cough
• Indications Refractory chronic cough; idiopathic pulmonary fibrosis (IPF) cough
• Key assets AF-219 (gefapixant; later MK-7264)
• Mechanism Selective oral P2X3 receptor antagonist

← Browse all deals  ·  How we score deals